NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio LLC, a clinical-stage biopharmaceutical company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders, today announced the hiring of Steven Tuch to lead the Company’s corporate development function. In this role, Mr. Tuch, a seasoned healthcare business professional, will have responsibility for Rallybio’s financing and capital allocation strategies and will also partner with the Business Development team to review and assess opportunities for transformative corporate deals, partnerships, and acquisitions.
“Steven’s impressive track record and broad range of industry experience advising various healthcare and biopharmaceutical companies on their financial strategy will play a crucial role in the growth of Rallybio as we continue to advance our pipeline and expand our portfolio,” said Steve Uden, Rallybio co-founder and Chief Operating Officer. “We are thrilled that Steven has joined the team and look forward to his contributions.”
Mr. Tuch brings over 30 years of financial experience to Rallybio, of which 25 years have been spent working with Life Science companies. Most recently, he served as Managing Director, Head of U.S. Equity Capital Markets Originations for BMO Capital Markets, where he was responsible for building the firm’s equity capital markets business. Prior to assuming that role, Mr. Tuch spent seven years as the Head of BMO’s Health Care Equity Capital Markets practice. While at BMO, Mr. Tuch completed over 140 transactions raising over $20 billion for his clients. Previously, he was a Managing Director at Deutsche Bank Securities where his roles included Head of Health Care Equity Capital Markets, Head of Consumer and Business Services Equity Capital Markets and Head of Equity Private Placements.
Commenting on his appointment, Mr. Tuch said, “I’m pleased to join this outstanding team of biotech leaders who are acutely focused on bringing transformative treatments to patients suffering from rare diseases. Their compassion for patients and caregivers, together with their demonstrated success in drug discovery and development is inspiring. I look forward to bringing my financial and corporate development experience to further support Rallybio’s important work.”
Mr. Tuch received an MBA from Stanford University’s Graduate School of Business and a BBA from the University of Michigan.
Rallybio is a clinical-stage biopharmaceutical company focused on identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. Since its launch in January 2018, Rallybio has built a portfolio of promising product candidates, which are now in development to address rare diseases in the areas of hematology, immuno-inflammation, and metabolism. The Company’s mission is being advanced by a team of highly experienced biopharma industry leaders with extensive research, development, and rare disease expertise. Rallybio is headquartered in New Haven, Connecticut, with an additional facility at the University of Connecticut’s Technology Incubation Program in Farmington, Connecticut. For more information, please visit www.rallybio.com.